ROR2 特异性 CAR-T 细胞对血液肿瘤和实体瘤有效且在小鼠中耐受良好

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice.

NKG2D/CD28 嵌合受体增强针对实体瘤和血液肿瘤的 CAR-T 细胞细胞毒性与持久性

NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors.

CAR 与 NKG2D/CD28 的联合提供了一种增强 CAR-T 细胞细胞毒性和持久性的有效策略。

RORing CAR-T 细胞在实体瘤与血液肿瘤中：相同却不同

RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.

平行处理 T 细胞与 NK 细胞以增强体内 CAR-T 细胞对血液肿瘤和实体瘤的活性

Parallel processing of T cells and natural killer cells to enhance in vivoCAR T cell activity against blood and solid cancers.

本研究鼓励优化利用白细胞单采产物。通过将废弃的 PBMC 回收为 NK 细胞，可有效增强 CAR-T 细胞疗法，改善肿瘤清除率和生存率。

利用多细胞因子颗粒平台工程化改良 CAR-T 细胞产品用于血液肿瘤和实体瘤

Engineering Improved CAR T Cell Products with A Multi-Cytokine Particle Platform for Hematologic and Solid Tumors.

CAR-T 细胞杀伤在实体瘤中依赖 IFNγR 通路，在血液肿瘤中不依赖

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.

释放 CAR-T 细胞治疗的潜力：血液肿瘤与实体瘤治疗中的进展、挑战与未来方向

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.

CAR-T 治疗中的抗原逃逸：从血液肿瘤到实体瘤的肿瘤微环境视角

Antigen escape in CAR-T therapy: A tumor microenvironment perspective from hematological to solid tumors.

CAR-T 治疗血液肿瘤与实体瘤的当前进展与挑战

Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.

尽管 CAR-T 疗法已经彻底改变了某些血液系统恶性肿瘤的治疗，但将其成功扩展到实体瘤仍面临重大障碍。持续的研究努力，聚焦于提高 CAR-T 细胞的疗效、安全性和可及性，对于在广泛癌症类型中充分释放这种创新免疫治疗方法的潜力至关重要。

CDK4/6 抑制增强实体瘤中的 CAR-T 细胞疗法

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors.